| 前收市價 | 27.95 |
| 開市 | 27.95 |
| 買盤 | 0.00 |
| 賣出價 | 0.00 |
| 拍板 | 1,020.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 27.95 - 27.95 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
Investor's Business DailyBeyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
- Zacks
ETFs to Profit from the Weight Loss Drug Boom
The market for GLP-1 drugs could soar to $130 billion by 2030
BenzingaEli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has granted Lilly global rights to develop and commercialize QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Under the terms of the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop an
